What Is Chemomab Therapeutics Ltd. (CMMB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Chemomab Therapeutics Ltd. presents a highly debated valuation profile at its current price of $1.65. The composite intrinsic value is estimated at $1.37 (-17.0% average upside), masking a wide model spread between the 4 bullish models and 4 bearish models. Model dispersion is worth noting: First Chicago targets $2.41 (+46.1%), versus Regime Cross at $0.21 (-87.2%). This +133.3% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About CMMB?
9 of 13 models are currently active for CMMB. Of these, 4 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates CMMB's intrinsic value at $0.48, implying -70.6% downside from the current price. See which stocks rank higher →
How Does CMMB Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, CMMB ranks #416 by Quality of Company score. CirclFi's QOC score of 2.2/10 evaluates 32 fundamental signals. A score of 2.2 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a biopharma enterprise, Chemomab Therapeutics Ltd. operates in a sector where revenue per drug is a critical driver of valuation. Investors evaluating CMMB should weigh these sector-specific dynamics alongside our model-derived fair values.
Is CMMB a Value Trap?
CirclFi's Value Trap algorithm assigns CMMB a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Chemomab Therapeutics Ltd.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Chemomab Therapeutics Ltd.'s fundamental quality profile registers 2.2/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +133.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CMMB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CMMB's 9 active models, average confidence is 11%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad